Clinical Trial Update: Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 [Phase 3]

View source ↗

Summary

Extension results from Phase 3 trials evaluating safety and efficacy of Turoctocog alfa (N8) for prophylaxis and on-demand treatment of bleeding in Haemophilia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Turoctocog alfa (N8) (turoctocog alfa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2017-07-27